{"id":"xuezhikang-capsule","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Liver enzyme elevation"}]},"_chembl":{"chemblId":"CHEMBL206253","moleculeType":"Small molecule","molecularWeight":"578.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Xuezhikang is a traditional Chinese medicine preparation derived from fermented red yeast rice (Monascus purpureus) that contains naturally occurring statins and other bioactive compounds. It lowers LDL cholesterol and triglycerides while raising HDL cholesterol, and also exhibits antiplatelet and antithrombotic properties that improve microcirculation and reduce cardiovascular risk.","oneSentence":"Xuezhikang reduces blood lipids and improves blood circulation by inhibiting cholesterol synthesis and modulating lipid metabolism through its active compounds derived from red yeast rice.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:16:25.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia and dyslipidemia"},{"name":"Coronary artery disease prevention and secondary prevention"},{"name":"Atherosclerosis"}]},"trialDetails":[{"nctId":"NCT02726555","phase":"PHASE3","title":"The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin","status":"RECRUITING","sponsor":"Wenzhou Medical University","startDate":"2015-11","conditions":"Dyslipidemia, Atherosclerosis","enrollment":240},{"nctId":"NCT05238012","phase":"PHASE4","title":"Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes","status":"COMPLETED","sponsor":"Heart Health Research Center","startDate":"2022-08-02","conditions":"Metabolism Disorder, Lipid, Metabolism Disorder, Glucose","enrollment":392},{"nctId":"NCT02603770","phase":"PHASE1","title":"Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2015-11","conditions":"Lipid Metabolism Disorder","enrollment":20},{"nctId":"NCT01327014","phase":"PHASE2","title":"Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Beijing Peking University WBL Biotech Co., Ltd.","startDate":"2011-04","conditions":"Hyperlipidemia","enrollment":116},{"nctId":"NCT02057302","phase":"PHASE4","title":"A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia","status":"COMPLETED","sponsor":"China Academy of Chinese Medical Sciences","startDate":"2010-03","conditions":"Dyslipidemia","enrollment":2400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XZK"],"phase":"marketed","status":"active","brandName":"Xuezhikang capsule","genericName":"Xuezhikang capsule","companyName":"China Academy of Chinese Medical Sciences","companyId":"china-academy-of-chinese-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xuezhikang reduces blood lipids and improves blood circulation by inhibiting cholesterol synthesis and modulating lipid metabolism through its active compounds derived from red yeast rice. Used for Hyperlipidemia and dyslipidemia, Coronary artery disease prevention and secondary prevention, Atherosclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}